Тромбозы и ревматические заболевания: частота встречаемости и механизмы развития (обзор и собственные данные)

1. <div><p>Thomas M. Venous thromboembolism - manifestations and diagnosis. Hospital Pharmacist 2006;13:199-204.</p><p>Tapson V.F. Acute pulmonary embolism. N Engl J Med 2008;358(10):1037-52.</p><p>Ageno W., Turpie A.G. Deep venous thrombosis in the medically ill. Curr Hematol Rep 2002;1(1):73-8.</p><p>Cervera R., Piette J.-Ch., Font J. et al. Antiphospholipid syndrome clinical and immunological manifestations and patterns of disease expression in cohort of 1000 patients. Arthr Rheum 2002;16(1):1019-27.</p><p>Решетняк Т.М., Александрова Е.Н., Мач Э.С. и др. Субклинические и клинические проявления атеросклероза при антифосфолипидном синдроме. Тер арх 2008;10:60-7.</p><p>Cervera R., Khamashta M.A., Font J. et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1999;78(3):167-75.</p><p>Woo K.-S., Kim K.-E., Kim J.-M. et al. Prevalence and clinical associations of Lupus anticoagulant, anticardiolipin antibodies and anti-Beta 2-glycoprotein 1 antibodies in patients with systemic lupus erythematosus. Korean J Lab Med 2010;30:38-44.</p><p>Ильина А.Е., Клюквина Н.Г., Александрова Е.Н. и др. Атеросклеротическое поражение сосудов при системной красной волчанке и антифосфолипидном синдроме у мужчин. Науч-практич ревматол 2005;5:4-10.</p><p>Голоева Р.Г., Алекберова З.С., Мач Э.С., Танковский В.Э. Сосудистые проявления болезни Бехчета. Науч-практич ревматол 2010;2:51-8.</p><p>Liang K.P, Liang K.V., Matteson E.L. et al. Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations. Arthr Rheum 2006;54(2):642-8.</p><p>Matta F., Singala R., Yaekoub A.Y. et al. Risk of venous thromboembolism with rheumatoid arthritis. Thromb Haemost 2009;101(1):134-8.</p><p>Wadhwa S. Deep vein thrombosis and haemolytic anaemia in a case of overlap syndrome. J Indian Acad Clin Med 2000;5(1):62-7.</p><p>Furey N.L., Schmid F.R., Kwaan H.C., Friederici H.H. Arterial thrombosis in scleroderma. Br J Dermatol 1975;93(6):683-93.</p><p>Liberati A.P., Ribeiro C.F., Skare T. Study about the association between anticardiolipin antibodies and peripheral vascular phenomena in patients suffering from systemic scleroderma. An Bras Dermatol 2010;85(3):403-5.</p><p>Huges G., Harris E., Gharavi A. The anticardiolipin syndrome. J Rheum 1986;13:486-9.</p><p>Baker W., Bick R. The clinical spectrum of antiphospholipid syndrome. Haematol Oncol Clin N Amer 2008;22:33-52.</p><p>Asherson R.A., Khamashta M.A., Ordi-Ros J. et al. The «primary» antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989;68(6):366-74.</p><p>Provenzale J.M., Ortel T.L., Allen N.B. Systemic thrombosis in patients with antiphospholipid antibodies: lesion distribution and imaging findings. Am J Roentgenol 1998;170(2):285-90.</p><p>Behcet H. Some observations on the clinical picture of the socalled triple symptom complex. Dermatologica 1940;81:73-83.</p><p>Saadoun D., Wechsler B., Desseaux K. et al. Mortality in Behcet's disease. Arthr Rheum 2010;62(9):2806-12.</p><p>Mehta R., Zaffan M., Hascard D. Thrombosis and Behcet's syndrome in non-endemic regions. Rheumatology 2010;49:2003-4.</p><p>Yazici H., Yurdakul S., Hamuryudan V. Behcet disease. Curr Opin Rheumatol 2001;13:18-22</p><p>Ben Ghorbel I., Ennaifer R., Lamloum M. et al. Budd-Chiari syndrome associated with Behcet's disease. Gastroenterol Clin Biol 2008;32(3):316-20.</p><p>Allenbach Y., Seror R., Pagnoux C. et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis 2009;68(4):564-7.</p><p>Ramagopalan S.V., Wotton C.J., Handel A.E. et al. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med 2011;10(9):1-9.</p><p>Sallai K.K., Nagy E., Bodo I. et al. Thrombosis risk in systemic lupus erythematosus: the role of thrombophilic risk factors. Scand J Rheumatol 2007;36(3):198-205.</p><p>Mok C.C., Ho L.Y., Yu K.L., To C.H. Venous thromboembolism in southern Chinese patients with systemic lupus erythematosus. Clin Rheumatol 2010;29(6):599-604.</p><p>Kaiser R., Barton J.L., Chang M. et al. Factor V Leiden and thrombosis in patients with systemic lupus erythematosus: a metaanalysis. Genes Immun 2009;10(5):495-502.</p><p>Tektonidou M.G., Laskari K., Panagiotakos D.B., Moutsopoulos</p><p>H.M. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthr Rheum 2009;15(61 Suppl. 1):29-36.</p><p>Asanuma Y., Oeser A., Shintani A.K. et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. New Eng J Med 2003;349:2407-15.</p><p>Romero-Diaz J., Garcia-Sosa I., Sanchez-Guerrero J. Thrombosis in systemic lupus erythematosus and other autoimmune diseases of recent onset. J Rheumatol 2009;36:68-75.</p><p>Zuber M., Kranzhöfer N., Lindemuth R. et al. A patient with mixed collagen disease, antiphospholipid syndrome and Sjögren syndrome. Med Klin (Munich) 1998;15(93 Suppl. 1):34-8.</p><p>Minenna G., Albanese L., D'Amore S. et al. Hereditary thrombophilia and systemic sclerosis. An unusual case report. Recenti Prog Med 2007;98(3):175-8.</p><p>Gupta R., Thabah M.M., Gupta S. Clinical significance of antiphospholipid antibodies in Indian scleroderma patients. Rheumatol Int 2009;23:12-4.</p><p>Tazawa R., Saijo Y., Abe T. et al. Pulmonary thromboembolism associated with antiphospholipid syndrome in scleroderma. Nihon Kyobu Shikkan Gakkai Zasshi 1997;35(12):1413-7.</p><p>Leite P.D., de Carvalho J.F. Systemic sclerosis sine scleroderma associated with antiphospholipid syndrome. Rheumatol Int 2010;9:35-8.</p><p>Zacharski L., Brown F., Memoli V. et al. Pathways of coagulation activation in situ in rheumatoid synovial tissue. Clin Immunol Immunopathol 1992;63:155-62.</p><p>Abernethy P.J. Surgery of the rheumatoid knee. Ann Rheum Dis 1990;49(2):830-6.</p><p>Van Heereveld H.A., Laan R.F., van den Hoogen F.H. et al. Prevention of symptomatic thrombosis with short term (low molecular weight) heparin in patients with rheumatoid arthritis after hip or knee replacement. Ann Rheum Dis 2001;60(10):974-6.</p><p>Virchow R. Gesammalte Alhandlungen zur Wissenschaftlichen Medizin. Frankfurt, Germany: Medinger Sohn, 1956;219-732.</p><p>Vaudo G., Marchesi S., Gerli R. et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004;63(1):31-5.</p><p>Gonzalez-Juanatey C., Testa A., Garcia-Castelo A. et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 2003;114(8):647-52.</p><p>Veale D.J., Maple C., Kirk G. et al. Soluble cell adhesion molecules - P-selectin and ICAM-1, and disease activity in patients receiving sulphasalazine for active rheumatoid arthritis. Scand J Rheumatol 1998;27(4):296-9.</p><p>Booth A.D., Jayne D.R., Kharbanda R.K. et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 2004;109(14):1718-23.</p><p>Науч-практич ревматол 2012; 50(1): 65-71</p><p>Koenig W. Haemostatic risk factors for cardiovascular diseases. Eur Heart J 1998;19(Suppl. C):C39-C43.</p><p>Zacharski L.R., Brown F.E., Memoli V.A. et al. Pathways of coagulation activation in situ in rheumatoid synovial tissue. Clin Immunol Immunopathol 1992;63(2):155-62.</p><p>Mameli A., Barcellona D., Marongiu F. et al. Rheumatoid arthritis and thrombosis. Clin Exp Rheumatol 2009;27(5):846-55.</p><p>Насонов Е.Л. Антифосфолипидный синдром. М.: Литтерра, 2004;73-99.</p><p>Leiba M., Seligsohn U., Sidi Y. et al. Thrombophilic factors are not the leading cause of thrombosis in Behcet's disease. Ann Rheum Dis 2004;63(11):1445-9.</p><p>Cerinic M.M., Valentini G., Sorano G.G. et al. Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthr Rheum 2003;32(5):285-95.</p><p>Von Depka M., Nowak-Göttl U., Eisert R. et al. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 2000;96(10):3364-8.</p><p>Feinbloom D., Bauer K.A. Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol 2005;25(10):2043-53.</p><p>Welch G.N., Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338(15):1042-50.</p><p>Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol 1967;13(3):269-88.</p><p>Davi G., Di Minno G., Coppola A. et al. Oxidative stress and platelet activation in homozygous homocystinuria. Circulation 2001;104(10):1124-8.</p><p>Booth G.L., Wang E.E. Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. The Canadian Task Force on Preventive Health Care. CMAJ 2000;163(1):21-9.</p><p>Lazzerini P.E., Capecchi P.L., Selvi E. et al. Hyperhomocysteinemia, inflammation and autoimmunity. Autoimmun Rev 2007;6(7):503-9.</p><p>Wolfe F. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol 1997;24(8):1477-85.</p><p>Knijff-Dutmer E.A., Koerts J., Nieuwland R. et al. Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthr Rheum 2002;46(6):1498-503.</p><p>Berckmans R.J., Nieuwland R., Tak P.P. et al. Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism. Arthr Rheum 2002;46(11):2857-66.</p><p>Berckmans R.J., Nieuwland R., Kraan M.C. et al. Synovial microparticles from arthritic patients modulate chemokine and cytokine release by synoviocytes. Arthr Res Ther 2005;7(3):536-44.</p><p>Disse J., Petersen H.H., Larsen K.S. et al. The endothelial protein C receptor supports tissue factor ternary coagulation initiation complex signaling through protease-activated receptors. J Biol Chem 2011;286(7):5756-67.</p><p>Grignani G., Maiolo A. Cytokines and hemostasis. Haematologica 2000;85(9):967-72.</p><p>Manzi S., Wasko M.C. Inflammation-mediated rheumatic diseases and atherosclerosis. Ann Rheum Dis 2000;59(5):321-5.</p><p>Jialal I., Devaraj S., Venugopal S.K. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004;44:6-11.</p><p>Nakagomi A., Freedman S.B., Geczy C. Interferon-γ and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein. Ralationship with age, sex, and hormone replacement treatment. Circulation 2000;101:1785-91.</p><p>Galli M., Finazzi G., Duca F. et al. The G1691 → A mutation of factor V, but not the G20210 → A mutation of factor II or the C677 → T mutation of methylenetetrahydrofolate reductase genes, is associated with venous thrombosis in patients with lupus anticoagulants. Br J Haematol 2000;108(4):865-70.</p><p>Topaloglu R., Akierli C., Bakkaloglu A. et al. Survey of factor V leiden and prothrombin gene mutations in systemic lupus erythematosus. Clin Rheumatol 2001;20(4):259-61.</p><p>Brouwer J.L., Bijl M., Veeger N.J., Kluin-Nelemans H.C. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 2004;104(1):143-8.</p><p>Arlestig L., Wallberg-Jonsson S., Stegmayr B. et al. Polymorphism of genes related to cardiovascular disease in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007; 25(6):866-71.</p><p>Wallberg-Jonsson S., Cvetkovic J.T., Sundqvist K.G. et al. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 2002;29(5):875-82.</p><p>Lockshin M.D. Update on antiphospholipid syndrome. Bull NYU Hosp Jt Dis 2006;64(12):57-9.</p><p>Afeltra A., Vadacca M., Conti L. et al. Thrombosis in systemic lupus erythematosus: congenital and acquired risk factors. Arthr Rheum 2005;53(3):452-9.</p><p>Olech E., Merrill J.T. The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis. Curr Rheumatol Rep 2006;8(2):100-8.</p><p>Filipowicz-Sosnowska A., Rupinski R., Walewska E. The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis. Pol Arch Med Wewn 2007;117(Suppl.):33-8.</p><p>Wolf P., Gretler J., Aglas F. et al. Anticardiolipin antibodies in rheumatoid arthritis: their relation to rheumatoid nodules and cutaneous vascular manifestations. Br J Dermatol 1994;131(1):48-51.</p><p>Eklund K., Peltomaa R., Leirisalo-Repo M. Occurence of pulmonary embolism during infliximab therapy. Clin Exp Rheumatol 2003;21(5):679.</p><p>Nosbaum A., Goujon C., Fleury B. et al. Arterial thrombosis with anti-phospholipid antibodies induced by infliximab. Eur J Dermatol 2007;17(6):546-7.</p><p>Makol A., Grover M., Guggenheim C. et al. Etanercept and venous thromboembolism: a case series. J Med Care Rep 2010;4:12.</p><p>Petitpain N., Gambier N., Wahl D. et al. Arterial and venous thromboembolic events during anti-TNF therapy: a study of 85 spontaneous reports in the period 2000-2006. Biomed Mater Eng 2009;19(4-5):355-64.</p><p>Алекберова З.С., Прокаева Т.В., Решетняк Т.М. и др. Анти-фосфолипидные антитела при болезни Бехчета. Клин мед 2000;5:37-8.</p><p>Ao W., Zheng H., Chen X.W. et al. Anti-annexin II antibody is associated with thrombosis and/or pregnancy morbidity in antiphospholipid syndrome and systemic lupus erythematosus with thrombosis. Rheumatol Int 2010;13:27-9.</p><p>Sweiss N.J., Bo R., Kapadia R. et al. IgA anti-beta2-glycoprotein I autoantibodies are associated with an increased risk of thromboembolic events in patients with systemic lupus erythematosus. PLoS One 2010;19:5(8).</p><p>Ortona E., Capozzi A., Colasanti T. et al. Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome. Blood 2010;116(16):2960-7.</p><p>Calamia K.T., Schirmer M., Melikoglu M. Major vessel involvement in Behcet's disease: an update. Curr Opin Rheumatol 2011;23(1):24-31.</p><p>Szekanecz Z., Koch A. Vascular involvement in rheumatic disease: «vascular rheumatology». Arthr Res Ther 2008;10(5):1-10.</p></div><br />